<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34716882</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1868-601X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Translational stroke research</Title>
          <ISOAbbreviation>Transl Stroke Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events.</ArticleTitle>
        <Pagination>
          <StartPage>410</StartPage>
          <EndPage>419</EndPage>
          <MedlinePgn>410-419</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12975-021-00956-8</ELocationID>
        <Abstract>
          <AbstractText>The relationship between RNF213 c.14429G &gt; A (p.Arg4810Lys) heterozygous variants and clinical manifestation in patients with Moyamoya disease (MMD) remains unclear. We performed a retrospective cohort analysis to clarify the genotype-phenotype correlation of this RNF213 hotspot variant in MMD patients, especially between wild-type (GG) and heterozygous (GA) genotypes. Clinical and genetic data were obtained from patients diagnosed with MMD in our institutions between October 2011 and November 2020. Clinical data included age, sex, neurological status at diagnosis, medical history, smoking history, alcohol intake, and family history. Of the 225 enrolled patients, 160 (71.1%) were symptomatic, 3 (1.3%) had the homozygous variant, and 149 (66.2%) had the heterozygous variant (GA). Analysis of all enrolled patients showed that the GA group was prone to present bilateral symptoms (p = 0.008) and progressive status (Suzuki grade ≥ 4; p = 0.017). Analysis limited to symptomatic patients revealed that the GA group had bilateral symptoms (p = 0.017), younger age at onset (p = 0.043), and, in particular, a higher proportion of onset before 25 years of age (p = 0.021). Multivariate logistic regression analysis of overall patients revealed that earlier age at diagnosis (p &lt; 0.001, OR 0.936, 95% CI 0.914-0.959) and GA group (p = 0.017, OR 3.326, 95%CI 1.237-8.941) were significantly associated with bilateral symptoms. MMD patients diagnosed at a young age with the RNF213 heterozygous variant should be followed up with consideration of possible contralateral stroke if one hemisphere is already symptomatic or of early cerebrovascular events if bilateral hemispheres are asymptomatic.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ishigami</LastName>
            <ForeName>Daiichiro</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyawaki</LastName>
            <ForeName>Satoru</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6369-3391</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. smiya-nsu@m.u-tokyo.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Hideaki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Masahiro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kanto Neurosurgery Hospital, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hongo</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dofuku</LastName>
            <ForeName>Shogo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohara</LastName>
            <ForeName>Kenta</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teranishi</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimada</LastName>
            <ForeName>Daisuke</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyorin University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koizumi</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ono</LastName>
            <ForeName>Hideaki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Fuji Brain Institute and Hospital, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirano</LastName>
            <ForeName>Yudai</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segawa</LastName>
            <ForeName>Masafumi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatomi</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyorin University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saito</LastName>
            <ForeName>Nobuhito</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Transl Stroke Res</MedlineTA>
        <NlmUniqueID>101517297</NlmUniqueID>
        <ISSNLinking>1868-4483</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="C557998">RNF213 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536991">Moyamoya disease 1</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Transl Stroke Res. 2021 Nov 26;:</RefSource>
          <PMID Version="1">34826044</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="Y">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="Y">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="Y">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bilateral cerebrovascular events</Keyword>
        <Keyword MajorTopicYN="Y">Genotype</Keyword>
        <Keyword MajorTopicYN="Y">Genotype–phenotype correlation</Keyword>
        <Keyword MajorTopicYN="Y">Moyamoya</Keyword>
        <Keyword MajorTopicYN="Y">RNF213</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>12</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34716882</ArticleId>
        <ArticleId IdType="doi">10.1007/s12975-021-00956-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s12975-021-00956-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Suzuki J, Takaku A. Cerebrovascular, “Moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288–99. https://doi.org/10.1001/archneur.1969.00480090076012 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1969.00480090076012</ArticleId>
            <ArticleId IdType="pubmed">5775283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56:34–40. https://doi.org/10.1038/jhg.2010.132 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jhg.2010.132</ArticleId>
            <ArticleId IdType="pubmed">21048783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for Moyamoya disease and its possible role in vascular development. PLoS One. 2011;6:e22542. https://doi.org/10.1371/journal.pone.0022542 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022542</ArticleId>
            <ArticleId IdType="pubmed">21799892</ArticleId>
            <ArticleId IdType="pmc">3140517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otten EG, Werner E, Crespillo-Casado A, Boyle KB, Dharamdasani V, Pathe C, et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature. 2021;594:111–6. https://doi.org/10.1038/s41586-021-03566-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03566-4</ArticleId>
            <ArticleId IdType="pubmed">34012115</ArticleId>
            <ArticleId IdType="pmc">7610904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, Youssefian S. A new horizon of Moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med. 2016;21:55–70. https://doi.org/10.1007/s12199-015-0498-7 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12199-015-0498-7</ArticleId>
            <ArticleId IdType="pubmed">26662949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G&gt;A variant of RNF213 predicts early-onset and severe form of Moyamoya disease. Neurology. 2012;78:803–10. https://doi.org/10.1212/WNL.0b013e318249f71f .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318249f71f</ArticleId>
            <ArticleId IdType="pubmed">22377813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, Saito N. Identification of a genetic variant common to Moyamoya disease and intracranial major artery stenosis/occlusion. Stroke. 2012;43:3371–4. https://doi.org/10.1161/STROKEAHA.112.663864 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.112.663864</ArticleId>
            <ArticleId IdType="pubmed">23010677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, et al. Genetic variant RNF213 c.14576G&gt;A in various phenotypes of intracranial major artery stenosis/occlusion. Stroke. 2013;44:2894–7. https://doi.org/10.1161/STROKEAHA.113.002477 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.113.002477</ArticleId>
            <ArticleId IdType="pubmed">23970789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang OY, Ryoo S, Kim SJ, Yoon CH, Cha J, Yeon JY, et al. Adult Moyamoya disease: a burden of intracranial stenosis in East Asians? PLoS One. 2015;10:e0130663. https://doi.org/10.1371/journal.pone.0130663 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0130663</ArticleId>
            <ArticleId IdType="pubmed">26125557</ArticleId>
            <ArticleId IdType="pmc">4488323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EH, Yum MS, Ra YS, Park JB, Ahn JS, Kim GH, et al. Importance of RNF213 polymorphism on clinical features and long-term outcome in Moyamoya disease. J Neurosurg. 2016;124:1221–7. https://doi.org/10.3171/2015.4.JNS142900 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.4.JNS142900</ArticleId>
            <ArticleId IdType="pubmed">26430847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nomura S, Yamaguchi K, Akagawa H, Kawashima A, Moteki Y, Ishikawa T, et al. Genotype-phenotype correlation in long-term cohort of Japanese patients with Moyamoya disease. Cerebrovasc Dis. 2019;47:105–11. https://doi.org/10.1159/000499699 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000499699</ArticleId>
            <ArticleId IdType="pubmed">30947170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YS Park HW Park HS Park CS Ryu JY Lee EJ Ko et al Association of genetic variants of RNF213 with ischemic stroke risk in Koreans Genes Genomics. 2021 https://doi.org/10.1007/s13258-020-01022-7</Citation>
        </Reference>
        <Reference>
          <Citation>Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for Moyamoya disease in the Chinese Han population. PLoS One. 2012;7:e48179. https://doi.org/10.1371/journal.pone.0048179 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048179</ArticleId>
            <ArticleId IdType="pubmed">23110205</ArticleId>
            <ArticleId IdType="pmc">3479116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene. 2013;526:437–42. https://doi.org/10.1016/j.gene.2013.05.083 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2013.05.083</ArticleId>
            <ArticleId IdType="pubmed">23769926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, et al. RNF213 as the major susceptibility gene for Chinese patients with Moyamoya disease and its clinical relevance. J Neurosurg. 2017;126:1106–13. https://doi.org/10.3171/2016.2.JNS152173 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2016.2.JNS152173</ArticleId>
            <ArticleId IdType="pubmed">27128593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang Z, Wei L, Zhang Q, Zou Z, Yang L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese Moyamoya disease. Neurology. 2020;94:e678–86. https://doi.org/10.1212/WNL.0000000000008901 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008901</ArticleId>
            <ArticleId IdType="pubmed">31949090</ArticleId>
            <ArticleId IdType="pmc">7176299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WH, Kim SD, Nam MH, Jung JM, Jin SW, Ha SK, et al. Posterior circulation involvement and collateral flow pattern in Moyamoya disease with the RNF213 polymorphism. Childs Nerv Syst. 2019;35:309–14. https://doi.org/10.1007/s00381-018-3985-5 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-018-3985-5</ArticleId>
            <ArticleId IdType="pubmed">30283986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge P, Ye X, Liu X, Deng X, Wang J, Wang R, et al. Association between p.R4810K variant and postoperative collateral formation in patients with Moyamoya disease. Cerebrovasc Dis. 2019;48:77–84. https://doi.org/10.1159/000503250 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503250</ArticleId>
            <ArticleId IdType="pubmed">31578010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Y Wang L Yang X Wang F Zeng K Zhang Q Zhang et al Meta-analysis of genotype and phenotype studies confirms predictive roles of the RNF213 p.R4810K for Moyamoya disease Eur J Neurol. 2020 https://doi.org/10.1111/ene.14635</Citation>
        </Reference>
        <Reference>
          <Citation>Research Committee on the P, Treatment of Spontaneous Occlusion of the Circle of W, Health Labour Sciences Research Grant for Research on Measures for Infractable D. Guidelines for diagnosis and treatment of Moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir. 2012;52:245–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.52.245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tominaga T, Suzuki N, Miyamoto S, Koizumi A, Kuroda S, Takahashi JC, et al. Recommendations for the management of Moyamoya disease: a statement from research committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) [2nd Edition]. Surgery for Cerebral Stroke. 2018;46:1–24. https://doi.org/10.2335/scs.46.1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2335/scs.46.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge P, Ye X, Liu X, Deng X, Wang R, Zhang Y, et al. Association Between p.R4810K Variant and long-term clinical outcome in patients with Moyamoya disease. Front Neurol. 2019;10:662. https://doi.org/10.3389/fneur.2019.00662 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.00662</ArticleId>
            <ArticleId IdType="pubmed">31293503</ArticleId>
            <ArticleId IdType="pmc">6603092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang SA, Song JS, Park TK, Yang JH, Kwon WC, Kim SR, et al. Nonsyndromic peripheral pulmonary artery stenosis is associated with homozygosity of RNF213 p.Arg4810Lys regardless of co-occurrence of Moyamoya disease. Chest. 2018;153:404–13. https://doi.org/10.1016/j.chest.2017.09.023 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2017.09.023</ArticleId>
            <ArticleId IdType="pubmed">28962888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano Y, Miyawaki S, Imai H, Hongo H, Ohara K, Dofuku S, et al. Association between the onset pattern of adult Moyamoya disease and risk factors for stroke. Stroke. 2020;51:3124–8. https://doi.org/10.1161/STROKEAHA.120.030653 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.120.030653</ArticleId>
            <ArticleId IdType="pubmed">32867597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao X, Deng J, Dai W, Zhang T, Yan J. Rare variants of RNF213 and Moyamoya/non-Moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Environ Health Prev Med. 2017;22:75. https://doi.org/10.1186/s12199-017-0680-1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12199-017-0680-1</ArticleId>
            <ArticleId IdType="pubmed">29165161</ArticleId>
            <ArticleId IdType="pmc">5667490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for Moyamoya disease. Brain Res. 2014;1552:64–71. https://doi.org/10.1016/j.brainres.2014.01.011 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.01.011</ArticleId>
            <ArticleId IdType="pubmed">24440776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi H, Yamazaki S, Takashima S, Liu W, Okuda H, Yan J, et al. Ablation of Rnf213 retards progression of diabetes in the Akita mouse. Biochem Biophys Res Commun. 2013;432:519–25. https://doi.org/10.1016/j.bbrc.2013.02.015 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.02.015</ArticleId>
            <ArticleId IdType="pubmed">23410753</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34716882</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1868-601X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Translational stroke research</Title>
          <ISOAbbreviation>Transl Stroke Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events.</ArticleTitle>
        <Pagination>
          <StartPage>410</StartPage>
          <EndPage>419</EndPage>
          <MedlinePgn>410-419</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12975-021-00956-8</ELocationID>
        <Abstract>
          <AbstractText>The relationship between RNF213 c.14429G &gt; A (p.Arg4810Lys) heterozygous variants and clinical manifestation in patients with Moyamoya disease (MMD) remains unclear. We performed a retrospective cohort analysis to clarify the genotype-phenotype correlation of this RNF213 hotspot variant in MMD patients, especially between wild-type (GG) and heterozygous (GA) genotypes. Clinical and genetic data were obtained from patients diagnosed with MMD in our institutions between October 2011 and November 2020. Clinical data included age, sex, neurological status at diagnosis, medical history, smoking history, alcohol intake, and family history. Of the 225 enrolled patients, 160 (71.1%) were symptomatic, 3 (1.3%) had the homozygous variant, and 149 (66.2%) had the heterozygous variant (GA). Analysis of all enrolled patients showed that the GA group was prone to present bilateral symptoms (p = 0.008) and progressive status (Suzuki grade ≥ 4; p = 0.017). Analysis limited to symptomatic patients revealed that the GA group had bilateral symptoms (p = 0.017), younger age at onset (p = 0.043), and, in particular, a higher proportion of onset before 25 years of age (p = 0.021). Multivariate logistic regression analysis of overall patients revealed that earlier age at diagnosis (p &lt; 0.001, OR 0.936, 95% CI 0.914-0.959) and GA group (p = 0.017, OR 3.326, 95%CI 1.237-8.941) were significantly associated with bilateral symptoms. MMD patients diagnosed at a young age with the RNF213 heterozygous variant should be followed up with consideration of possible contralateral stroke if one hemisphere is already symptomatic or of early cerebrovascular events if bilateral hemispheres are asymptomatic.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ishigami</LastName>
            <ForeName>Daiichiro</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyawaki</LastName>
            <ForeName>Satoru</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6369-3391</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. smiya-nsu@m.u-tokyo.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Hideaki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Masahiro</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kanto Neurosurgery Hospital, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hongo</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dofuku</LastName>
            <ForeName>Shogo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohara</LastName>
            <ForeName>Kenta</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teranishi</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimada</LastName>
            <ForeName>Daisuke</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyorin University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koizumi</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ono</LastName>
            <ForeName>Hideaki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Fuji Brain Institute and Hospital, Shizuoka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirano</LastName>
            <ForeName>Yudai</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segawa</LastName>
            <ForeName>Masafumi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatomi</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyorin University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saito</LastName>
            <ForeName>Nobuhito</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Transl Stroke Res</MedlineTA>
        <NlmUniqueID>101517297</NlmUniqueID>
        <ISSNLinking>1868-4483</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="C557998">RNF213 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536991">Moyamoya disease 1</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Transl Stroke Res. 2021 Nov 26;:</RefSource>
          <PMID Version="1">34826044</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="Y">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="Y">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="Y">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Bilateral cerebrovascular events</Keyword>
        <Keyword MajorTopicYN="Y">Genotype</Keyword>
        <Keyword MajorTopicYN="Y">Genotype–phenotype correlation</Keyword>
        <Keyword MajorTopicYN="Y">Moyamoya</Keyword>
        <Keyword MajorTopicYN="Y">RNF213</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>12</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34716882</ArticleId>
        <ArticleId IdType="doi">10.1007/s12975-021-00956-8</ArticleId>
        <ArticleId IdType="pii">10.1007/s12975-021-00956-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Suzuki J, Takaku A. Cerebrovascular, “Moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20:288–99. https://doi.org/10.1001/archneur.1969.00480090076012 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1969.00480090076012</ArticleId>
            <ArticleId IdType="pubmed">5775283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56:34–40. https://doi.org/10.1038/jhg.2010.132 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jhg.2010.132</ArticleId>
            <ArticleId IdType="pubmed">21048783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for Moyamoya disease and its possible role in vascular development. PLoS One. 2011;6:e22542. https://doi.org/10.1371/journal.pone.0022542 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022542</ArticleId>
            <ArticleId IdType="pubmed">21799892</ArticleId>
            <ArticleId IdType="pmc">3140517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otten EG, Werner E, Crespillo-Casado A, Boyle KB, Dharamdasani V, Pathe C, et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature. 2021;594:111–6. https://doi.org/10.1038/s41586-021-03566-4 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03566-4</ArticleId>
            <ArticleId IdType="pubmed">34012115</ArticleId>
            <ArticleId IdType="pmc">7610904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, Youssefian S. A new horizon of Moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med. 2016;21:55–70. https://doi.org/10.1007/s12199-015-0498-7 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12199-015-0498-7</ArticleId>
            <ArticleId IdType="pubmed">26662949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G&gt;A variant of RNF213 predicts early-onset and severe form of Moyamoya disease. Neurology. 2012;78:803–10. https://doi.org/10.1212/WNL.0b013e318249f71f .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318249f71f</ArticleId>
            <ArticleId IdType="pubmed">22377813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, Saito N. Identification of a genetic variant common to Moyamoya disease and intracranial major artery stenosis/occlusion. Stroke. 2012;43:3371–4. https://doi.org/10.1161/STROKEAHA.112.663864 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.112.663864</ArticleId>
            <ArticleId IdType="pubmed">23010677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, et al. Genetic variant RNF213 c.14576G&gt;A in various phenotypes of intracranial major artery stenosis/occlusion. Stroke. 2013;44:2894–7. https://doi.org/10.1161/STROKEAHA.113.002477 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.113.002477</ArticleId>
            <ArticleId IdType="pubmed">23970789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang OY, Ryoo S, Kim SJ, Yoon CH, Cha J, Yeon JY, et al. Adult Moyamoya disease: a burden of intracranial stenosis in East Asians? PLoS One. 2015;10:e0130663. https://doi.org/10.1371/journal.pone.0130663 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0130663</ArticleId>
            <ArticleId IdType="pubmed">26125557</ArticleId>
            <ArticleId IdType="pmc">4488323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EH, Yum MS, Ra YS, Park JB, Ahn JS, Kim GH, et al. Importance of RNF213 polymorphism on clinical features and long-term outcome in Moyamoya disease. J Neurosurg. 2016;124:1221–7. https://doi.org/10.3171/2015.4.JNS142900 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.4.JNS142900</ArticleId>
            <ArticleId IdType="pubmed">26430847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nomura S, Yamaguchi K, Akagawa H, Kawashima A, Moteki Y, Ishikawa T, et al. Genotype-phenotype correlation in long-term cohort of Japanese patients with Moyamoya disease. Cerebrovasc Dis. 2019;47:105–11. https://doi.org/10.1159/000499699 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000499699</ArticleId>
            <ArticleId IdType="pubmed">30947170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>YS Park HW Park HS Park CS Ryu JY Lee EJ Ko et al Association of genetic variants of RNF213 with ischemic stroke risk in Koreans Genes Genomics. 2021 https://doi.org/10.1007/s13258-020-01022-7</Citation>
        </Reference>
        <Reference>
          <Citation>Wu Z, Jiang H, Zhang L, Xu X, Zhang X, Kang Z, et al. Molecular analysis of RNF213 gene for Moyamoya disease in the Chinese Han population. PLoS One. 2012;7:e48179. https://doi.org/10.1371/journal.pone.0048179 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048179</ArticleId>
            <ArticleId IdType="pubmed">23110205</ArticleId>
            <ArticleId IdType="pmc">3479116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene. 2013;526:437–42. https://doi.org/10.1016/j.gene.2013.05.083 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2013.05.083</ArticleId>
            <ArticleId IdType="pubmed">23769926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, et al. RNF213 as the major susceptibility gene for Chinese patients with Moyamoya disease and its clinical relevance. J Neurosurg. 2017;126:1106–13. https://doi.org/10.3171/2016.2.JNS152173 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2016.2.JNS152173</ArticleId>
            <ArticleId IdType="pubmed">27128593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang Z, Wei L, Zhang Q, Zou Z, Yang L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese Moyamoya disease. Neurology. 2020;94:e678–86. https://doi.org/10.1212/WNL.0000000000008901 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008901</ArticleId>
            <ArticleId IdType="pubmed">31949090</ArticleId>
            <ArticleId IdType="pmc">7176299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WH, Kim SD, Nam MH, Jung JM, Jin SW, Ha SK, et al. Posterior circulation involvement and collateral flow pattern in Moyamoya disease with the RNF213 polymorphism. Childs Nerv Syst. 2019;35:309–14. https://doi.org/10.1007/s00381-018-3985-5 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-018-3985-5</ArticleId>
            <ArticleId IdType="pubmed">30283986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge P, Ye X, Liu X, Deng X, Wang J, Wang R, et al. Association between p.R4810K variant and postoperative collateral formation in patients with Moyamoya disease. Cerebrovasc Dis. 2019;48:77–84. https://doi.org/10.1159/000503250 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503250</ArticleId>
            <ArticleId IdType="pubmed">31578010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Y Wang L Yang X Wang F Zeng K Zhang Q Zhang et al Meta-analysis of genotype and phenotype studies confirms predictive roles of the RNF213 p.R4810K for Moyamoya disease Eur J Neurol. 2020 https://doi.org/10.1111/ene.14635</Citation>
        </Reference>
        <Reference>
          <Citation>Research Committee on the P, Treatment of Spontaneous Occlusion of the Circle of W, Health Labour Sciences Research Grant for Research on Measures for Infractable D. Guidelines for diagnosis and treatment of Moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir. 2012;52:245–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.52.245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tominaga T, Suzuki N, Miyamoto S, Koizumi A, Kuroda S, Takahashi JC, et al. Recommendations for the management of Moyamoya disease: a statement from research committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) [2nd Edition]. Surgery for Cerebral Stroke. 2018;46:1–24. https://doi.org/10.2335/scs.46.1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2335/scs.46.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge P, Ye X, Liu X, Deng X, Wang R, Zhang Y, et al. Association Between p.R4810K Variant and long-term clinical outcome in patients with Moyamoya disease. Front Neurol. 2019;10:662. https://doi.org/10.3389/fneur.2019.00662 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2019.00662</ArticleId>
            <ArticleId IdType="pubmed">31293503</ArticleId>
            <ArticleId IdType="pmc">6603092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang SA, Song JS, Park TK, Yang JH, Kwon WC, Kim SR, et al. Nonsyndromic peripheral pulmonary artery stenosis is associated with homozygosity of RNF213 p.Arg4810Lys regardless of co-occurrence of Moyamoya disease. Chest. 2018;153:404–13. https://doi.org/10.1016/j.chest.2017.09.023 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2017.09.023</ArticleId>
            <ArticleId IdType="pubmed">28962888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano Y, Miyawaki S, Imai H, Hongo H, Ohara K, Dofuku S, et al. Association between the onset pattern of adult Moyamoya disease and risk factors for stroke. Stroke. 2020;51:3124–8. https://doi.org/10.1161/STROKEAHA.120.030653 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.120.030653</ArticleId>
            <ArticleId IdType="pubmed">32867597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao X, Deng J, Dai W, Zhang T, Yan J. Rare variants of RNF213 and Moyamoya/non-Moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Environ Health Prev Med. 2017;22:75. https://doi.org/10.1186/s12199-017-0680-1 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12199-017-0680-1</ArticleId>
            <ArticleId IdType="pubmed">29165161</ArticleId>
            <ArticleId IdType="pmc">5667490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonobe S, Fujimura M, Niizuma K, Nishijima Y, Ito A, Shimizu H, et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: a susceptibility gene for Moyamoya disease. Brain Res. 2014;1552:64–71. https://doi.org/10.1016/j.brainres.2014.01.011 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2014.01.011</ArticleId>
            <ArticleId IdType="pubmed">24440776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi H, Yamazaki S, Takashima S, Liu W, Okuda H, Yan J, et al. Ablation of Rnf213 retards progression of diabetes in the Akita mouse. Biochem Biophys Res Commun. 2013;432:519–25. https://doi.org/10.1016/j.bbrc.2013.02.015 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.02.015</ArticleId>
            <ArticleId IdType="pubmed">23410753</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
